Executive summary

Topical therapies are uniquely positioned to deliver targeted treatment with minimal systemic exposure, but translation from lab efficacy to real-world effectiveness is frequently limited by formulation and delivery challenges. Problems such as chemical and physical instability, inconsistent dosing, poor aesthetic properties and difficult application can reduce adherence and impact clinical outcomes. However, when methodically formulated, engineered and packaged, foams and advanced semi-solid dispersions can successfully overcome many of these limitations.

This whitepaper outlines how foam formulations and optimized packaging systems, including a novel Bag-on-Valve (BoV) patented technology and aerosols, can improve stability, dosing uniformity, patient adherence and market differentiation. By reviewing scientific trade-offs — solubilization versus suspension, particle engineering and excipient strategies — topical drug delivery developers can achieve foams with both performance and pleasing sensory attributes. Container–closure systems are equally important, protecting product integrity and enabling precise dispensing throughout the product life cycle.

The right combination of formulation science, process engineering and packaging expertise can transform complex ideas into launch-ready products. By partnering with pharmaceutical sponsors, Formulated Solutions helps mitigate technical risks, accelerate development timelines and deliver differentiated topical therapies that perform in the real world.

Formulating small molecule APIs into foams requires solving a network of interconnected problems, including ensuring chemical and physical stability, controlling rheology and selecting packaging that maintains performance. Each decision influences not only bioavailability, but also the patient's experience and the manufacturability of the final product.

Formulation integrity over time

Topical dispersions must remain stable throughout manufacture, distribution and patient use. Instability threatens both dosing accuracy and patient trust. Common risks include:

• Phase separation: Density differences between the continuous phase and suspended particles can lead to sedimentation, producing non-uniform doses.
• Oxidative degradation: APIs and excipients prone to oxidation can lose potency and may generate odor or color changes.
• Microbial growth: Water-based systems require reliable preservative systems or risk contamination.
• Viscosity drift: Changes in temperature, polymer breakdown or solvent migration can alter viscosity, affecting spreadability and dose delivery.

Mitigation requires a coordinated approach that combines formulation controls and process controls. Formulation strategies include using antioxidants and chelators to slow oxidative pathways and incorporating robust preservative systems, validated by Preservative Efficacy Testing, to prevent microbial growth. Rheology modifiers are selected to both resist sedimentation and maintain the product's desirable texture and feel. Process control strategies are equally important and involve optimizing manufacturing parameters such as homogenization energy, temperature and the order of ingredient addition to achieve a reproducible and stable product microstructure.

Solubility vs. suspension strategies

Topical APIs can often present solubility challenges. For instance, an API may be poorly soluble in water but soluble in an oil phase, necessitating a two-part emulsion system. This requires developers to carefully evaluate solubilization and suspension delivery strategies.

• Solubilized delivery dissolves the API in the vehicle, often enhancing permeation and uniformity. However, solubilization can demand cosolvents or surfactants that increase irritation risks or destabilize the system.
• Suspension delivery disperses the API as solid particles, which may improve chemical stability but increases the risk of sedimentation and dosing inconsistency if not properly engineered.

Stability testing must also be comprehensive. Beyond real-time shelf studies, stress testing under thermal, oxidative, light, freeze–thaw and agitation conditions ensures confidence in performance. Rheology and particle distribution monitoring over time confirm dosing consistency.

The optimal choice balances bioavailability, tolerability and manufacturability. Useful strategies include surfactant or polymeric solubilizers to maintain dissolution, cyclodextrin complexation to enhance solubility without excessive surfactant use, and rheology controls that immobilize suspended particles. Hybrid approaches — where part of the API is solubilized for rapid onset and the remainder suspended for sustained release — are also available, offering the best of both worlds.

Impact of API particle size and surface characteristics

Particle engineering is central to suspension stability and bioavailability:

• Micronization and nanosizing reduce settling velocity and increase apparent surface area, potentially improving dissolution rate and absorption.
• Surface coatings can either be lipidic or polymeric and reduce particle aggregation, modulate wettability and can include protective antioxidants for labile APIs.
• Complexation with carriers (e.g., cyclodextrins) modifies solubility and surface energy, improving distribution in the vehicle.

Analytical control via laser diffraction, dynamic light scattering and microscopy ensures particle size distributions remain within the design window. Surface analysis also helps predict interfacial interactions that influence sedimentation and compatibility with excipients.

Adherence and human factors are as important as formulation. A topically active API cannot achieve a clinical effect if patients avoid or inconsistently apply therapy.

Special populations

• Pediatrics: application reluctance is a common barrier — foams reduce the tactile struggle for caregivers and children by being quick-drying, non-sticky and easy to dose, using low-irritancy, fragrance-free excipient sets and low-force actuators.
• Geriatrics: many older adults have impaired dexterity or cognitive challenges. BoV dispensers with ergonomically optimized actuators and predictable outputs lower the physical demand of dosing and reduce spills.
• Specialty uses: burn care, scar management and rare dermatologic disorders often involve fragile skin or irregular surfaces; foam's gentle, non-abrasive application and superior spreadability make it an attractive option.

Adherence behavior and real-world use

Behavioral research consistently shows that sensory attributes shape long-term use. Greasy formulations cause social stigma and non-use, and sticky or strongly fragranced products can provoke irritation or aversion. Sensory endpoints that support adherence include minimal residue, rapid drying, neutral scent options and a pleasant finish.

Real-world data and market research should be integrated into formulation endpoints. Sensorial panels, clinician feedback and small-scale human factors studies early in development prevent late-stage setbacks and shape excipient choices that balance stability with patient appeal.

We combine formulation chemistry, particle engineering, process design and packaging integration in an end-to-end model:

• Science-driven formulation: our teams optimize solubilization vs. suspension strategies, select permeation enhancers and design rheology systems to balance stability with patient experience.
• Particle and surface engineering: micronization, nanoformulation and surface coatings are leveraged where they deliver measurable improvements in uniformity and bioavailability.
• Packaging integration: formulations are co-engineered with a range of containment systems, including aerosols and our novel, patented BoV technologies.
• Regulatory & quality support: analytical method development (HPLC, particle sizing, rheology, headspace oxygen), extraction/leachable evaluation and stability protocols support CMC sections and shelf-life claims.

Our track record is solving the hard problems that allow topical products to succeed in the marketplace — robust chemistries, patient-centric delivery and manufacturable processes.